Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: JAK Inhibitor Safety in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: JAK Inhibitor Safety in IBD

Summary

This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Maintenance data for selective JAKs in Crohn's disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trials

- Selective JAKs' expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs are broadly positive about TOF's safety profile in UC, highlighting TOF's relative comparability to safety seen in other indications

- Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity

- Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our 10 key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based

- Interviews performed during March 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

JAK inhibitor, IBD, safety


Companies

Pfizer

Gilead

Galapagos

GSK

AbbVie

Company Profile

Company Profile Title

KOL Perspectives: JAK Inhibitor Safety in IBD

Summary

This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Maintenance data for selective JAKs in Crohn's disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trials

- Selective JAKs' expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs are broadly positive about TOF's safety profile in UC, highlighting TOF's relative comparability to safety seen in other indications

- Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity

- Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our 10 key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based

- Interviews performed during March 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

JAK inhibitor, IBD, safety


Companies

Pfizer

Gilead

Galapagos

GSK

AbbVie